BrainsWay to Showcase Advanced TMS Solutions at a Major Event
BrainsWay Announces Sponsorship at Key Industry Meeting
BURLINGTON, Mass. and JERUSALEM – BrainsWay Ltd. (NASDAQ: BWAY), a leader in noninvasive neurostimulation treatments for mental health issues, is thrilled to announce their Gold Sponsorship of the Clinical TMS Society’s Annual Meeting from June 12 to June 14. This event will take place in San Diego, California, and BrainsWay is eager to present its groundbreaking Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, alongside compelling new research that illustrates the advantages of their advancements in mental health treatment.
Highlighting Clinical Education Sessions
On June 14, BrainsWay will host a pertinent morning session titled “Accelerating Relief: Multicenter RCT Results from a Novel H1 Coil Accelerated Deep TMS Depression Protocol.” The presentation will be led by Colleen Hanlon, PhD, who serves as the Vice President of Clinical & Medical Affairs at BrainsWay. Through this educational session, stakeholders will gain insight into the early results from a significant multicenter randomized trial comparing the Company’s traditional Deep TMS depression protocol with a new accelerated approach, utilizing their proprietary H1 Coil effectively.
Deep TMS Clinical Research Insights
During the conference, the latest findings in Deep TMS research will be prominently showcased at various poster presentation sessions, featuring:
- Deep TMS for Smoking Cessation: Outcomes from a Phase IV Registry Study of the H4 Coil. This study revealed that 49% of participants successfully quit smoking and experienced reduced cravings after undergoing 15 treatment sessions with the H4 Coil.
- Safety and Efficacy of Deep TMS for Adolescent Depression. A post-marketing surveillance study analyzed data from over 1,200 adolescent patients across 56 sites and affirmed the safety and efficacy of Deep TMS for this demographic.
- H1 Coil Stimulation Sites That Improve Depression Coverage. A third-party investigation utilized electric field modeling and neuroimaging to determine optimal positioning of the H1 Coil for effective depression treatment.
Interactive Demonstrations at the Exhibit Hall
Attendees will also have the chance to engage directly with BrainsWay’s advanced Deep TMS system during hands-on demonstrations at their booth in the exhibit hall. This interactive experience will allow visitors to observe the unique advantages of Deep TMS compared to traditional first-generation therapies.
About BrainsWay
BrainsWay stands at the forefront of innovation in neurostimulation treatments for mental health disorders. By leveraging the power of its proprietary Deep TMS technology, the Company is on a mission to enhance healthcare outcomes and transform lives. BrainsWay is the first and only TMS organization to receive FDA clearance for three distinct indications, based on pivotal clinical studies verifying its efficacy. The current indications encompass major depressive disorder, obsessive-compulsive disorder, and nicotine addiction. Continuously striving for excellence, BrainsWay emphasizes rigorous scientific methodologies and relies on its extensive clinical evidence base. The company has numerous additional trials underway exploring Deep TMS's applications across various psychiatric and neurological conditions. Founded in 2003, BrainsWay operates in both the United States and Israel and is dedicated to raising global awareness and expanding access to its life-changing Deep TMS technology.
Frequently Asked Questions
What is BrainsWay's role at the Clinical TMS Society Annual Meeting?
BrainsWay is a Gold Sponsor of the Annual Meeting and will showcase its innovative Deep TMS technology.
Who will present during the clinical education session?
The session will be presented by Colleen Hanlon, PhD, the Vice President of Clinical & Medical Affairs at BrainsWay.
What groundbreaking research will be reported at the conference?
Research focusing on the efficacy of Deep TMS for smoking cessation and adolescent depression will be highlighted through poster presentations.
What does Deep TMS aim to treat?
Deep TMS is designed to treat various mental health disorders, including major depressive disorder and obsessive-compulsive disorder.
How does BrainsWay ensure the innovation of its products?
BrainsWay emphasizes continuous research and clinical trials to develop its Deep TMS technology, striving for advancements in treatment efficacy and safety.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.